Drug intelligence / Profile preview

IGN381

Development stage: Unknown
Lead developer: Igenica Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IGN381 is a monoclonal antibody developed by Igenica Biotherapeutics as a first-in-class immunotherapy targeting the VISTA immune checkpoint. VISTA (V-domain Ig suppressor of T cell activation) is an inhibitory receptor expressed on immune infiltrates that suppresses T-cell activation in the tumor microenvironment, contributing to immune evasion in cancer. IGN381 aims to block VISTA to enhance anti-tumor immune responses, with preclinical data supporting its potential in solid and hematological malignancies; it was part of Igenica's antibody portfolio before the company's asset sale in 2017.

Targets

VISTA

Beyond the preview

Go deeper on IGN381.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGN381.

Explore the full profile